Edition:
United States

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,406JPY
2:00am EDT
Change (% chg)

¥12 (+0.27%)
Prev Close
¥4,394
Open
¥4,400
Day's High
¥4,465
Day's Low
¥4,399
Volume
4,504,800
Avg. Vol
4,348,161
52-wk High
¥6,693
52-wk Low
¥4,203

Latest Key Developments (Source: Significant Developments)

Seattle Genetics And Takeda Announce Positive Results From Phase 3 Echelon-2 Clinical Trial Evaluating Adcetris
Monday, 1 Oct 2018 07:17am EDT 

Oct 1 (Reuters) - Seattle Genetics Inc ::SEATTLE GENETICS AND TAKEDA ANNOUNCE POSITIVE RESULTS FROM PHASE 3 ECHELON-2 CLINICAL TRIAL EVALUATING ADCETRIS® (BRENTUXIMAB VEDOTIN) IN FRONTLINE CD30-EXPRESSING PERIPHERAL T-CELL LYMPHOMA.ADCETRIS IN COMBINATION WITH CHEMOTHERAPY ACHIEVED PRIMARY ENDPOINT.FIRST RANDOMIZED PHASE 3 TRIAL TO SHOW IMPROVEMENT IN OVERALL SURVIVAL IN FRONTLINE PERIPHERAL T-CELL LYMPHOMA.STATISTICALLY SIGNIFICANT IMPROVEMENT ACHIEVED IN ALL KEY SECONDARY ENDPOINTS, INCLUDING OVERALL SURVIVAL IN PHASE 3 TRIAL.INTENDS TO SUBMIT SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION TO FDA FOR APPROVAL IN NEAR FUTURE.  Full Article

Takeda Pharmaceutical To Present Positive Data From Alunbrig Alta-1L Trial
Tuesday, 25 Sep 2018 08:32am EDT 

Sept 25 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA TO PRESENT POSITIVE DATA FROM ALUNBRIG® (BRIGATINIB) ALTA-1L TRIAL SHOWING A REDUCTION IN RISK OF DISEASE PROGRESSION OR DEATH OF MORE THAN 50 PERCENT VERSUS CRIZOTINIB IN FIRST-LINE ADVANCED ALK+ NSCLC.TAKEDA - ALTA-1L MET PRIMARY ENDPOINT SHOWING SUPERIORITY IN BLINDED INDEPENDENT REVIEW COMMITTEE-ASSESSED PROGRESSION-FREE SURVIVAL COMPARED TO CRIZOTINIB.TAKEDA PHARMACEUTICAL - SAFETY PROFILE ASSOCIATED WITH ALUNBRIG WAS GENERALLY CONSISTENT WITH EXISTING U.S. PRESCRIBING INFORMATION.  Full Article

Seattle Genetics Announces Adcetris Approval In Japan
Friday, 21 Sep 2018 10:48am EDT 

Sept 21 (Reuters) - Seattle Genetics Inc ::SEATTLE GENETICS ANNOUNCES ADCETRIS® (BRENTUXIMAB VEDOTIN) APPROVAL IN JAPAN FOR FRONTLINE HODGKIN LYMPHOMA.SEATTLE GENETICS INC - JAPANESE APPROVAL TRIGGERS MILESTONE PAYMENT TO CO OF $10 MILLION.  Full Article

EMA Recommendations For August 2018
Friday, 21 Sep 2018 07:10am EDT 

Sept 21 (Reuters) - European Medicines Agency::EUROPEAN MEDICINES AGENCY RECOMMENDATIONS FOR AUGUST 2018.RECOMMENDS APPROVAL OF ELI LILLY’S GALCANEZUMAB.RECOMMENDS APPROVAL OF TAKEDA’S BRIGATINIB.RECOMMENDS APPROVAL OF SPARK THERAPEUTICS’ VORETIGENE NEPARVOVEC LUXTURNA.RECOMMENDS APPROVAL OF BAYER’S DAMOCTOCOG ALFA PEGOL .  Full Article

Molecular Templates Announces Deal With Takeda
Wednesday, 19 Sep 2018 08:00am EDT 

Sept 19 (Reuters) - Molecular Templates Inc ::MOLECULAR TEMPLATES ANNOUNCES AGREEMENT WITH TAKEDA FOR THE JOINT DEVELOPMENT OF A PROTEIN-BASED ONCOLOGY THERAPY.MOLECULAR TEMPLATES INC - TAKEDA WILL MAKE AN UPFRONT PAYMENT OF $30 MILLION.MOLECULAR TEMPLATES - CO ELIGIBLE TO RECEIVE DEVELOPMENT, OTHER MILESTONE PAYMENTS OF UPTO $632.5 MILLION IF CO EXERCISES ITS CO-DEVELOPMENT OPTION.MOLECULAR TEMPLATES - ELIGIBLE TO RECEIVE DEVELOPMENT, OTHER MILESTONE PAYMENTS OF $337.5 MILLION IF IT DOESN'T EXERCISE OR OPTS OUT OF CO-DEVELOPMENT OPTION.MOLECULAR TEMPLATES INC - TAKEDA HAS ALSO AGREED TO PAY ROYALTIES ON SALES OF COMMERCIAL PRODUCT DEVELOPED THROUGH COLLABORATION.MOLECULAR TEMPLATES - AGREEMENT WITH TAKEDA PHARMACEUTICAL COMPANY LIMITED FOR JOINT DEVELOPMENT OF CD38-TARGETED ENGINEERED TOXIN BODIES.  Full Article

Takeda Is Said To Weigh Sale Of Shire Eye Care Drug To Cut Debt - Bloomberg
Thursday, 13 Sep 2018 02:51am EDT 

Sept 13 (Reuters) - :TAKEDA IS SAID TO WEIGH SALE OF SHIRE EYE CARE DRUG TO CUT DEBT - BLOOMBERG, CITING SOURCES.  Full Article

Takeda Pharmaceutical completes acquisition of TiGenix following expiration of squeeze-out period
Tuesday, 31 Jul 2018 02:31am EDT 

July 31(Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>:Says it completes its acquisition of TiGenix following expiration of the squeeze-out period.Takeda has acquired all outstanding ordinary shares(including ordinary shares represented by American Depositary Shares) and warrants of TiGenix following the expiration of the squeeze-out period.  Full Article

Takeda Q1 Earnings Per Share JPY 100
Tuesday, 31 Jul 2018 02:00am EDT 

July 31 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA REPORTS FIRST QUARTER FY2018 RESULTS.Q1 EARNINGS PER SHARE JPY 100.00.  Full Article

Takeda Pharmaceutical Announces Statement Regarding US FTC Clearance
Tuesday, 10 Jul 2018 02:11am EDT 

July 10 (Reuters) - Takeda Pharmaceutical Company Ltd <4502.T>::STATEMENT REGARDING US FTC CLEARANCE.TAKEDA RECEIVES CLEARANCE FROM UNITED STATES FEDERAL TRADE COMMISSION FOR PROPOSED ACQUISITION OF SHIRE PLC.  Full Article

Takeda And Tigenix Announce Results Of Second Acceptance Period For The Voluntary And Conditional Public Takeover Bid
Friday, 6 Jul 2018 01:00am EDT 

July 6 (Reuters) - Tigenix Nv ::TAKEDA AND TIGENIX ANNOUNCE RESULTS OF SECOND ACCEPTANCE PERIOD FOR THE VOLUNTARY AND CONDITIONAL PUBLIC TAKEOVER BID IN RESPECT OF TIGENIX AND COMMENCEMENT OF SIMPLIFIED SQUEEZE-OUT AND INTENTION TO DELIST THE ADSS FROM NASDAQ....FOLLOWING SETTLEMENT OF SECURITIES, TAKEDA WILL OWN 96.08% OF OUTSTANDING ORDINARY SHARES.THE SQUEEZE-OUT PERIOD WILL COMMENCE TODAY, JULY 6, 2018, AND WILL EXPIRE ON JULY 26, 2018.  Full Article

Photo

Takeda's $62 billion Shire bid faces November 6 EU antitrust deadline

BRUSSELS EU antitrust regulators will decide by Nov. 6 whether to allow Japanese drugmaker Takeda Pharmaceutical's $62-billion takeover of London-listed Shire Plc , the European Commission said on Friday.